Xarelto was approved by the U.S. Food and Drug Administration (FDA) in July 2011 to reduce the risk of pulmonary embolism and deep vein thrombosis (DVT) in hip and knee replacement patients. The drug was later approved to reduce stroke and blood clot risks in patients with atrial fibrillation.
Within the first quarter of 2012, the FDA received 356 adverse event reports about Xarelto, according to QuarterWatch. Some of the more serious reports involved Xarelto and bleeding internally without an antidote to reverse the drug’s blood thinning effects. Xarelto bleeding incidents accounted for 34 percent of the adverse events.
A Xarelto user who sustains an injury can suffer from unstoppable internal bleeding after just one dose.
Xarelto users who were hospitalized for substantial bleeding and those who lost a loved one who took Xarelto are urged to contact a Xarelto lawyer to protect their legal rights. Filing a lawsuit against the drug’s manufacturers can make them take responsibility for their failure to advise Xarelto users to monitor their blood levels.
Greg Spizer is a partner of Anapol Weiss and co-chairs the firm's Mass Tort Department. He concentrates his practice on pharmaceutical liability, professional malpractice, products liability and other civil and commercial litigation.